Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Change in Receivables: 2020-2024

Historic Change in Receivables for Fulcrum Therapeutics (FULC) over the last 5 years, with Dec 2024 value amounting to $1.6 million.

  • Fulcrum Therapeutics' Change in Receivables fell 141.96% to -$979,000 in Q2 2025 from the same period last year, while for Jun 2025 it was -$2.3 million, marking a year-over-year decrease of 239.12%. This contributed to the annual value of $1.6 million for FY2024, which is 406.17% up from last year.
  • Per Fulcrum Therapeutics' latest filing, its Change in Receivables stood at $1.6 million for FY2024, which was up 406.17% from $308,000 recorded in FY2023.
  • Over the past 5 years, Fulcrum Therapeutics' Change in Receivables peaked at $2.0 million during FY2020, and registered a low of -$2.5 million during FY2022.
  • Moreover, its 3-year median value for Change in Receivables was $308,000 (2023), whereas its average is -$211,000.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Change in Receivables plummeted by 512.54% in 2022, and later soared by 406.17% in 2024.
  • Yearly analysis of 5 years shows Fulcrum Therapeutics' Change in Receivables stood at $2.0 million in 2020, then tumbled by 69.70% to $606,000 in 2021, then crashed by 512.54% to -$2.5 million in 2022, then surged by 112.32% to $308,000 in 2023, then soared by 406.17% to $1.6 million in 2024.